Xtampza ER (Oxycodone Myristate) Patent Expiration, LOE Window & CMS Spending
Xtampza ER (Oxycodone Myristate) by Collegium: FDA Orange Book LOE 2036-09-02, 14 AB generics, $260.6M 2024 CMS Part D & Medicaid spend, and 10 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Collegium |
| FDA Application & Pathway | N208090 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2036-09-02 |
| Orange Book Patents (*PED Extensions) | 8 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 14 |
| 2024 CMS Total Public Spend | $260.6M |
| 2024 Medicare Part D Spend | $232.8M |
| 2024 Medicaid Spend | $27.9M |
| Reported Wholesale Price Change (CA SB 17) | 10 WAC filings (max 26.8% 2-yr change) |